http://orcid.org/0000-0001-7939-7204
Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Olga Pitsillidou, Panagiotis Petrou & M. J. Postma. (2023) Implementing a Managed Entry Agreement Framework in Cyprus. Expert Review of Pharmacoeconomics & Outcomes Research 23:8, pages 857-865.
Read now
Read now
Margit Gombocz & Sabine Vogler. (2020) Public spending on orphan medicines: a review of the literature. Journal of Pharmaceutical Policy and Practice 13:1.
Read now
Read now
Szymon Jarosławski & Mondher Toumi. (2019) Non-profit drug research and development: the case study of Genethon. Journal of Market Access & Health Policy 7:1.
Read now
Read now
Articles from other publishers (13)
Raymond Vanholder, Lieven Annemans, Marion Braks, Edwina A. Brown, Priya Pais, Tanjala S. Purnell, Simon Sawhney, Nicole Scholes-Robertson, Bénédicte Stengel, Elliot K. Tannor, Vladimir Tesar, Arjan van der Tol & Valérie A. Luyckx. (2023) Inequities in kidney health and kidney care. Nature Reviews Nephrology 19:11, pages 694-708.
Crossref
Crossref
Małgorzata Skweres-Kuchta, Iwona Czerska & Elżbieta Szaruga. (2023) Literature Review on Health Emigration in Rare Diseases—A Machine Learning Perspective. International Journal of Environmental Research and Public Health 20:3, pages 2483.
Crossref
Crossref
Benjamin Roth. 2023. Medizin – Technik – Ethik. Medizin – Technik – Ethik
127
150
.
Tatiana Foltanova, Alan Majernik, Eva Malikova & Stanislava Kosirova. (2022) Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010–2019. Frontiers in Pharmacology 13.
Crossref
Crossref
Khadidja Abdallah, Kris De Boeck, Marc Dooms & Steven Simoens. (2021) A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Europe. Frontiers in Pharmacology 12.
Crossref
Crossref
Jong Hyuk Lee. (2021) Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison. Healthcare 9:3, pages 296.
Crossref
Crossref
Difei Geng & Kamal Saggi. (2020) Optimal price regulations in international pharmaceutical markets with generic competition. Journal of Health Economics 71, pages 102315.
Crossref
Crossref
Marina Morgado Garcia, Pamela Santos Azevedo, Andrew Mirelman, Leandro Pinheiro Safatle, Roberto Iunes, Marion Clark Bennie, Brian Godman & Augusto Afonso Guerra Junior. (2020) Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario.. Frontiers in Pharmacology 11.
Crossref
Crossref
Monique Dabbous, Lylia Chachoua, Aleksandra Caban & Mondher Toumi. (2020) Managed Entry Agreements: Policy Analysis From the European Perspective. Value in Health 23:4, pages 425-433.
Crossref
Crossref
Marcin Czech, Aleksandra Baran-Kooiker, Kagan Atikeler, Maria Demirtshyan, Kamilla Gaitova, Malwina Holownia-Voloskova, Adina Turcu-Stiolica, Coen Kooiker, Oresta Piniazhko, Natella Konstandyan, Olha Zalis'ka & Jolanta Sykut-Cegielska. (2020) A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries. Frontiers in Public Health 7.
Crossref
Crossref
Lucio Luzzatto, Enrico Costa, Arrigo Schieppati & Giuseppe Remuzzi. (2019) Orphan drugs – Authors' reply. The Lancet 393:10181, pages 1595-1596.
Crossref
Crossref
Szymon Jarosławski, Eve Hanna, Monique Dabbous, Lylia Chachoua & Mondher Toumi. 2019. Regulatory and Economic Aspects in Oncology. Regulatory and Economic Aspects in Oncology
39
55
.
Hye-Young Kwon, Hyungmin Kim & Brian Godman. (2018) Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications. Frontiers in Pharmacology 9.
Crossref
Crossref